Related Experiment Video
Updated: May 11, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Reversibility of structural and functional damage in a model of advanced diabetic nephropathy
Warangkana Pichaiwong1, Kelly L Hudkins, Tomasz Wietecha
1Department of Pathology, University of Washington, Seattle, Washington 98195, USA.
Abstract:
The reversibility of diabetic nephropathy remains controversial. Here, we tested whether replacing leptin could reverse the advanced diabetic nephropathy modeled by the leptin-deficient BTBR ob/ob mouse. Leptin replacement, but not inhibition of the renin-angiotensin-aldosterone system (RAAS), resulted in near-complete reversal of both structural (mesangial matrix expansion, mesangiolysis, basement membrane thickening, podocyte loss) and functional (proteinuria, accumulation of reactive oxygen species) measures of advanced diabetic nephropathy. Immunohistochemical labeling with the podocyte markers Wilms tumor 1 and p57 identified parietal epithelial cells as a possible source of regenerating podocytes. Thus, the leptin-deficient BTBR ob/ob mouse provides a model of advanced but reversible diabetic nephropathy for further study. These results also suggest that restoration of lost podocytes is possible but is not induced by RAAS inhibition, possibly explaining the limited efficacy of RAAS inhibitors in promoting repair of diabetic nephropathy.
Insights
Leptin replacement reversed advanced diabetic nephropathy in mice, unlike renin-angiotensin-aldosterone system inhibition. This suggests leptin therapy may restore lost podocytes, offering new insights into diabetic kidney disease treatment.
Area of Science:
- Nephrology
- Endocrinology
- Diabetology
Background:
- Diabetic nephropathy (DN) reversibility is debated.
- Leptin deficiency exacerbates DN.
- BTBR ob/ob mice model advanced DN.
Purpose of the Study:
- To investigate leptin replacement for reversing advanced DN in BTBR ob/ob mice.
- To compare leptin's effects with renin-angiotensin-aldosterone system (RAAS) inhibition.
- To explore podocyte regeneration mechanisms in DN.
Main Methods:
- Utilized leptin-deficient BTBR ob/ob mice to model advanced diabetic nephropathy.
- Administered leptin replacement therapy.
- Inhibited the renin-angiotensin-aldosterone system (RAAS).
- Assessed structural (mesangial matrix, podocyte loss) and functional (proteinuria, oxidative stress) markers of DN.
- Used immunohistochemistry for podocyte markers (Wilms tumor 1, p57).
Main Results:
- Leptin replacement nearly fully reversed structural and functional DN markers.
- RAAS inhibition did not reverse advanced diabetic nephropathy.
- Parietal epithelial cells were identified as a potential source for regenerating podocytes.
- Podocyte regeneration was observed following leptin therapy.
Conclusions:
- Advanced diabetic nephropathy in BTBR ob/ob mice is reversible with leptin replacement.
- Leptin therapy, not RAAS inhibition, promotes podocyte regeneration.
- This study provides a model for reversible advanced DN and suggests novel therapeutic strategies.
Related Concept Videos
Diabetic Nephropathy
Diabetic Neuropathy
Chronic Kidney Disease I: Introduction
Diabetic Retinopathy
